Jettisoning revenue

Aeterna Zentaris Inc. expects the $50 million it gained from spinning out its Atrium Biotechnologies Inc. specialty chemicals and nutraceutical division will allow it to get to multiple valuation inflection points in the coming years, including an NDA submission in mid-2009 for a benign prostatic hyperplasia therapeutic.

Aeterna (TSX:AEZ; AEZS, Quebec City, Quebec) was formed in 1991 as a company with a hybrid business model: biotech R&D and a commercial division focused on active ingredients. Revenues from the latter were funneled back into R&D. ...